May 6, 2020 NIAID Funding News
Read this full edition online at http://www.niaid.nih.gov/
Feature Articles
New R01, R21 Pair of COVID-19 Emergency FOAs With Rolling Submission
These funding opportunity announcements are ideal for applicants proposing new coronavirus-related research projects. They feature rolling submission, meaning you can submit an application as soon as it is ready and NIAID will review it in an expedited fashion.
Opportunities and Resources
Researchers based outside of Canada may collaborate on research applications to address COVID-19 as principal applicants, co-applicants, or collaborators.
Improve understanding of Mycobacterium tuberculosis-host interactions by characterizing bacterial and host determinants that are relevant during stages of infection and disease as well as analyzing bacterial and host heterogeneity on disease outcomes.
Apply for funding to study how best to trigger multiple adaptive T and B cell responses, and possibly innate immunity, to prevent or limit the initial infection or elicit responses that contain and eliminate HIV virus.
NIAID will support innovative, rigorous, well-designed studies that enhance our knowledge of disease processes and provide evidence-based solutions to improve the diagnosis, treatment, and quality of life for persons with ME/CFS.
The Indo-U.S. Science and Technology Forum is supporting two research and development (R&D) call for proposals to create virtual networks for joint research activities and develop new technologies, tools, and systems to address COVID-19-related challenges.
In The News
To address common questions from training (T), fellowship (F), or career development (K) award recipients, NIH posted instructions for awardees to contact program and grants management staff to explain COVID-19 delays or barriers to research.
NIH issued new instructions for peer reviewers that state, “Assume that issues resulting from the coronavirus pandemic will be resolved prior to award, and [do] not allow concerns about temporary, emergency situations to affect [overall impact] scores.”
NIAID published the NIAID Strategic Plan for COVID-19 Research for fiscal years 2020 to 2024 to explain our priorities for understanding the virus—how it causes disease and strategies to mitigate illness and death.
Advice Corner
Use this article to learn about our organization and NIAID Career Opportunities, find vacancy announcements, and get tips on the unique government job application process.
Reader Questions
New Funding Opportunities
- PA-20-183, Research Project Grant (Parent R01, Clinical Trial Required)
- PA-20-185, NIH Research Project Grant (Parent R01, Clinical Trial Not Allowed)
- PA-20-188, NIH Pathway to Independence Award (Parent K99/R00, Independent Clinical Trial Not Allowed)
- NOT-OD-20-104, Notice of Special Interest—Administrative Supplements for NIH grants to Add or Expand Research Focused on Maternal Mortality
- PAR-20-177, Emergency Awards Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21, Clinical Trial Not Allowed)
- PAR-20-178, Emergency Awards Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01, Clinical Trial Not Allowed)
- RFA-AI-20-027, Mucosal Immunology Studies Team (MIST) (U01, Clinical Trial Not Allowed)
- PA-20-166, Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)
- Immunology Quality Assessment (IQA) Program
- PAR-20-167, Lasker Clinical Research Scholars Program (Si2/R00, Clinical Trial Optional)
Find other announcements at NIAID Opportunities & Announcements.
Send suggestions or comments to deaweb@niaid.nih.gov.
.png)
No hay comentarios:
Publicar un comentario